50jili
A Fort Worth company that produces a line of lighter-than-air unmanned airships has earned a key certification from the Federal Aviation Administration, paving the way for widespread adoption of the technology. Galaxy Unmanned Systems LLC , a TechFW client, earned FAA certification for the first set of its line of unmanned airships weighing more than 55 pounds, marking a groundbreaking achievement in Advanced Air Mobility, according to the company. Advanced Air Mobility, or AAM, is a new sector of the aerospace industry which aims to safely and efficiently integrate highly automated aircraft into the current airspace infrastructure, according to the FAA. The FAA decision is important to Galaxy, but it also means other companies can begin development with similar technologies. “This certification isn’t just a win for Galaxy—it’s a breakthrough for the aviation industry,” Galaxy CEO Jason White said in a statement. “Our lighter-than-air technology airships represent the future of unmanned systems, combining autonomy, sustainability and unmatched operational flexibility.” The FAA approval covers Galaxy’s GC35-E2, GC35-E4 and GC50-E4 models – airships designed for extended operations, heavy payloads and integration into national airspace. The platforms open opportunities across commercial and defense applications, including: Surveillance: elevated, wide-area monitoring for security operations. Broadcasting: improved coverage for large-scale events. Event security: safeguarding festivals, rallies and high-profile venues. Counter-unmanned aircraft system operations: cost-effective detection and mitigation of rogue drones. Disaster relief: delivery of communication and situational tools to areas hit by natural disasters such as hurricanes, tornadoes or fires. Search and rescue: enhanced aerial support for locating individuals. Get essential daily news for the Fort Worth area. Sign up for insightful, in-depth stories — completely free. Galaxy Unmanned Systems is led by brothers Tony and Jason White, who grew up flying remote-controlled aircraft, worked their way up through the commercial side of the unmanned aircraft systems industry, and then headed to the U.S. Department of Defense. Their combined more than 40 years of work includes concept, design, manufacturing, certification, testing, payload configuration, subsystem integration, documentation, training and operations. Galaxy’s certified airships are designed for industries requiring cost-effective solutions, and are uniquely suited for missions that traditional aircraft cannot fulfill, according to Jason White. “With this certification, we’re excited to continue our conversations and move forward as a partner with commercial and government leaders to explore their needs and our possibilities,” he said. Galaxy’s certification was a long process, going back over 17 years. In 2007, the FAA suspended commercial drone operations in the National Airspace System, halting Galaxy’s early advancements in unmanned airship technology, according to Jason White. That decision left hundreds of pioneering companies, including Galaxy, in limbo. “Momentum resumed in 2018 with regulatory updates, allowing exemptions for unmanned aircraft exceeding 55 pounds,” said Tony White, Galaxy’s COO. Galaxy has worked with research partners from the University of Texas at Arlington in developing its technology. Galaxy submitted its certification request in May 2024. “The FAA’s approval is the result of a lot of employee efforts, diligence and patience,” Tony White said in a statement. “We hope to push the boundaries of air mobility, pave the way for innovative operations in restricted airspace, delivering solutions that are safer, smarter, and more sustainable.” Bob Francis is business editor for the Fort Worth Report. Contact him at bob.francis@fortworthreport.org. At the Fort Worth Report, news decisions are made independently of our board members and financial supporters. Read more about our editorial independence policy here . Related Fort Worth Report is certified by the Journalism Trust Initiative for adhering to standards for ethical journalism . Republish This Story Republishing is free for noncommercial entities. Commercial entities are prohibited without a licensing agreement. Contact us for details. This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License . Look for the "Republish This Story" button underneath each story. To republish online, simply click the button, copy the html code and paste into your Content Management System (CMS). Do not copy stories straight from the front-end of our web-site. You are required to follow the guidelines and use the republication tool when you share our content. The republication tool generates the appropriate html code. You can’t edit our stories, except to reflect relative changes in time, location and editorial style. You can’t sell or syndicate our stories. Any web site our stories appear on must include a contact for your organization. If you use our stories in any other medium — for example, newsletters or other email campaigns — you must make it clear that the stories are from the Fort Worth Report. In all emails, link directly to the story at fortworthreport.org and not to your website. If you share our stories on social media, please tag us in your posts using @FortWorthReport on Facebook and @FortWorthReport on Twitter. You have to credit Fort Worth Report. Please use “Author Name, Fort Worth Report” in the byline. If you’re not able to add the byline, please include a line at the top of the story that reads: “This story was originally published by Fort Worth Report” and include our website, fortworthreport.org . You can’t edit our stories, except to reflect relative changes in time, location and editorial style. Our stories may appear on pages with ads, but not ads specifically sold against our stories. You can’t sell or syndicate our stories. You can only publish select stories individually — not as a collection. Any web site our stories appear on must include a contact for your organization. If you share our stories on social media, please tag us in your posts using @FortWorthReport on Facebook and @FortWorthReport on Twitter. by Bob Francis, Fort Worth Report December 19, 2024EVANSVILLE, Ind. (AP) — Tayshawn Comer scored 18 points as Evansville beat Campbell 66-53 on Sunday night. Comer had six rebounds and six assists for the Purple Aces (3-4). Cameron Haffner scored 16 points and added six rebounds. Gabriel Pozzato shot 3 for 5, including 2 for 3 from beyond the arc to finish with 10 points. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.Spurs at 76ers Odds, predictions, recent stats, trends and Best bets for December 23
Cetera Strengthens Executive Leadership to Propel Strategic Growth and Innovation
BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers. This acquisition expands OraSure’s innovation pipeline with the addition of Sherlock’s molecular diagnostics platform, which is able to provide rapid results with strong sensitivity and specificity in a disposable format that is well-suited for over-the-counter usage. Sherlock’s first molecular self-test is for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) which will expand OraSure’s portfolio of rapid diagnostics for sexually transmitted infections (STIs), subject to regulatory approvals. Test results are expected to be provided in under 30 minutes by analyzing DNA and RNA from self-collected swabs using isothermal amplification. In addition, Sherlock has been developing a pipeline of other molecular tests, along with several next-generation technology platforms, including Ambient Temperature Amplification and CRISPR-based technologies that have the potential to further reduce costs and improve performance of its platforms. Sherlock’s CT/NG self-test is in clinical studies and is expected to be submitted to the FDA by the end of 2025 for review. Subject to regulatory approvals, revenue from Sherlock’s CT/NG test is expected to contribute to OTI’s growth beginning in 2026, benefitting from OraSure’s existing infrastructure, commercial capabilities, and strong customer relationships. OTI estimates that testing for CT/NG represents a total addressable market of more than $1.5 billion. The vast majority of CT/NG tests in the U.S. are processed in a centralized lab, and the introduction of an affordable, rapid self-test has the potential to drive significant incremental market expansion. Additionally, public health channels play a key role in STI screening, which is an area where OraSure has a strong presence. “The acquisition of Sherlock represents the next step in OTI’s innovation strategy,” said Carrie Eglinton Manner, President and CEO of OraSure. “Sherlock brings valuable capabilities with an advanced molecular platform that aims to deliver lab-like accuracy in a format that expands access to diagnostic insights through convenient, effortless tests. We are excited to welcome Sherlock’s talented team to OTI and believe that Sherlock’s unique capabilities will contribute significantly to the expansion of our pipeline of diagnostic tests in infectious disease, sexual health, and beyond.” Conference Call Information OraSure will host a conference call to discuss the acquisition of Sherlock Biosciences at 5:00 p.m. ET on Thursday, Dec. 19, 2024. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations . Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure’s website shortly after the call has ended and will be available for approximately 90 days. To participate in the live conference call, please follow the link below to pre-register. After registering, you will be provided with access details via email. https://register.vevent.com/register/BIb938f5bae2a442d9acdb83f4bdd9286d About OraSure Technologies, Inc. OraSure Technologies, Inc. (“OraSure”) transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiary, DNA Genotek Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com Forward Looking Statements This press release contains certain “forward-looking statements” within the meaning of the Federal securities laws, including with respect to products, product development and manufacturing activities, the Company’s acquisition of Sherlock, revenue growth, cash flow, increasing margins and other matters. Words such as “expects,” “estimates,” “forecasts,” “intends,” “plans,” “projects,” “could,” “may,” “should,” “will” or other similar words and expressions are intended to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: the Company’s ability to integrate Sherlock's business and achieve the intended benefits of the acquisition on the timeline expected or at all; Sherlock’s ability to seek and obtain regulatory approval for products in development; the Company’s ability to satisfy customer demand; ability to reduce the Company’s spending rate, capitalize on manufacturing efficiencies and drive profitable growth; ability to achieve the anticipated cost savings as a result of the Company’s business restructuring, including from insourcing third party manufacturing and exiting microbiome services; ability to market and sell products, whether through the Company’s internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for the Company’s products; ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the FDA or other regulators; the impact of the novel coronavirus (“COVID-19”) pandemic on the Company’s business, supply chain, labor force, ability to successfully develop new products, validate the expanded use of existing collector products, receive necessary regulatory approvals and authorizations and commercialize such products for COVID-19 testing, and demand for the Company’s COVID-19 testing products; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to meet increased demand for the Company’s products; impact of replacing distributors; inventory levels at distributors and other customers; ability of the Company to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales and the ability to continue to reduce costs; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid or urine testing, collection or other products; market acceptance and uptake of microbiome informatics, microbial genetics technology and related analytics services; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of the Company’s products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to maintain sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company’s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; cybersecurity breaches or other attacks involving the Company’s systems or those of the Company’s third-party contractors and IT service providers; the impact of terrorist attacks, civil unrest, hostilities and war; and general political, business and economic conditions, including inflationary pressures and banking stability. These and other factors that could affect the Company’s results are discussed more fully in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Company’s registration statements, Annual Report on Form 10-K for the year ended December 31, 2023, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and the Company undertakes no duty to update these statements.
NoneGary Lineker has denounced notorious Arsenal fan channel AFTV after some fresh obscene remarks about the players from select supporters. The Match of the Day host was seemingly taken aback by some of the most recent viral posts. One abhorrent piece of criticism directed at captain Martin Odegaard even showed Gunners fan Lee Judges – a regular guest on AFTV – saying he "would've shot" Odegaard if he "had a gun" after Arsenal's 0-0 draw with Everton a little over a week ago . While Lineker didn't specifically mention Judges by name or the social media post in question, he admitted that clips from the YouTube channel ventured on the "vicious" side off the back of the disappointing result. Arsenal struggled to break Everton down and would have considered it two points dropped in their battle with Liverpool and Chelsea for the title. Gunners supporter Judges was notably frustrated with Odegaard, who's not been on his best form of late for Mikel Arteta's side and found himself being substituted after 64 minutes against the struggling Toffees. Discussing the channel that has over 1.7million subscribers on YouTube and has gained mass media attention in the past from the likes of Sky Sports, Lineker told his fellow The Rest is Football podcast co-hosts Alan Shearer and Micah Richards last week that brutal comments like the ones he heard will not help the team in their chase for a first Premier League title since 2004. "Do you ever see that Arsenal TV thing," Lineker asked, before adding: "Sometimes I get clips come up on Instagram or whatever, and goodness me, some of the fans were laying into their players. "You think, ‘crikey’ – like viciously, it was horrible. I don’t know how they think that’s going to help if you’re slaughtering your own players to that degree. "Especially when they’re clearly giving everything week in, week out. It’s not easy playing against a team [ Everton ] that sits with 10 men behind the ball for the entire game." Created in 2012 by Arsenal fan Robbie Lyle, AFTV has grown to become one of the biggest football fan channels in the world and have conducted interviews with club legends such as Thierry Henry and Ian Wright. But part of its popularity is actually with rival fan bases who relish seeing the meltdowns from Arsenal fans after a bad day at the office. While Arsenal got back to winning ways with successive victories over Crystal Palace – 3-2 at home in the Carabao Cup quarter finals followed by a 5-1 thumping away in the league on Saturday (December 21) – their last win came at a price with Bukayo Saka coming off injured. He's set to be out of action for "many weeks" , according to Arteta, after suffering a hamstring tear. "It's not looking good, he's going to be out for many weeks," the Spaniard revealed. Arsenal's first game without the England winger will come at home against Ipswich Town this Friday (December 27). Amazon's Prime Video is broadcasting the Premier League Boxing Day round of fixtures on December 26-27. Each match can be streamed free with an Amazon Prime subscription or by signing up for an Amazon Prime 30-day free trial . Join our new WhatsApp community and receive your daily dose of Mirror Football content. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. If you're curious, you can read our Privacy Notice.